Research Roundup: Vitamin D, Treat-to-Target, Tocilizumab for Giant Cell Arteritis

March 31, 2016

Vitamin D’s failed treatment to prevent tibial cartilage loss and tocilizumab for giant cell arteritis represent a small sample of studies of interest that were published in top journals this month.

Vitamin D’s failed treatment to prevent tibial cartilage loss; treat-to-target for quality of life in rheumatoid arthritis; tocilizumab for giant cell arteritis; the protective role of sclerostin in TNF-mediated chronic inflammation and mind-body medicine for lower back pain represent a small sample of studies of interest that were published in top journals this month.

Published Online: 04 March 2016DOI: http://dx.doi.org/10.1016/S0140-6736(16)00560-2Source: The Lancet

DOI: http://dx.doi.org/10.1016/S0140-6736(16)00477-3Volume 387, Special Issue, S90, 25 February 2016Source: The Lancet

Vol. 8, Issue 330, pp. 330ra35DOI: 10.1126/scitranslmed.aac4351March 16, 2016Source: Science Translational Medicine

DOI:10.1001/jama.2016.2437March 22/29, 2016, Vol 315, No. 12EditorialSource: JAMA

Research Roundup: Vitamin D, Treat-to-Target, Tocilizumab for Giant Cell Arteritis

Rheumatology Network Staff